MedTrace Logo

Efficacy and Safety of Two Doses of Liarozole vs. Placebo for the Treatment of Lamellar Ichthyosis

NCT00282724 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 98

Last updated 2011-09-26

No results posted yet for this study

Summary

Lamellar ichthyosis is a congenital disease of the skin with a generalized scaling. The primary activity of liarozole is considered to be the inhibition of the degradation of a substance called retinoic acid, which is the principal endogenous regulator of growth and differentiation of epithelial tissues in mammals. The current study intends to evaluate the efficacy and safety in patients with lamellar ichthyosis.

Conditions

  • Ichthyosis, Lamellar

Interventions

DRUG

Liarozole

Sponsors & Collaborators

  • Stiefel, a GSK Company

    lead INDUSTRY

Principal Investigators

  • Koen van Rossem, MD, PhD · Barrier Therapeutics/ Stiefel, a GSK Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2007-04-30
Completion
2007-04-30

Countries

  • Belgium
  • Canada
  • Dominican Republic
  • France
  • Germany
  • Italy
  • Netherlands
  • Norway
  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00282724 on ClinicalTrials.gov